Neovascular Age-related Macular Degeneration: Intraocular Inflammatory Cytokines in the Non-responder to Ranibizumab Treatment
Phase of Trial: Phase IV
Latest Information Update: 18 Oct 2018
Price : $35 *
At a glance
- Drugs Ranibizumab (Primary) ; Aflibercept
- Indications Wet age-related macular degeneration
- Focus Therapeutic Use
- 09 Oct 2018 Status changed from active, no longer recruiting to completed.
- 31 Aug 2018 Biomarkers information updated
- 04 Jan 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.